Clinical Trials on Moderate Language Delay in Singapore

Total 13 results

Nanyang Technological University

Recruiting

Reducing Anxiety Problems Among Children Indicated to Have Developmental Language Disorder (RAP-iDLD)

Developmental Language Disorder and Language Impairment | Anxiety Disorders and Symptoms

Singapore
National University Health System, Singapore

Completed

The Effectiveness of Computerized Auditory Training Programme on Children With Auditory Processing Disorder (CBAT)

Central Auditory Processing Disorder

Singapore
National Healthcare Group, Singapore

Completed

Web-Based CBT Protocol for Treatment of Selective Mutism

Selective Mutism

Singapore
Danone Nutricia Research

Terminated

An Exploratory Study to Compare the Differences in Nutritional Status Between Patients With Mild and Moderate Alzheimer's Disease (AD) and Cognitively Intact Healthy People in an Asian Population

Mild and Moderate Alzheimer's Disease | Cognitively Healthy People

Singapore
Singapore Eye Research Institute

Unknown

Safety and Efficacy of Tissue Engineered Endothelial Keratoplasty (TE-EK)

Fuchs' Endothelial Dystrophy | Bullous Keratopathy | Mild to Moderate Corneal Endothelial Decompensation | Post-surgical Corneal Decompensation (Irreversible)

Singapore
Novartis

Completed

Efficacy and Safety of the Combination of Aliskiren (300 mg) and Amlodipine (10 mg) Compared to Amlodipine (10 mg) Monotherapy in Patients With Moderate to Severe Hypertension

Moderate to Severe Hypertension

Russian Federation, Romania, Singapore, Spain, Germany, Philippines
Novartis Pharmaceuticals

Completed

Efficacy and Safety of Subcutaneous Secukinumab (AIN457) for Moderate to Severe Chronic Plaque-type Psoriasis Assessing Different Doses and Dose Regimens (SCULPTURE)

Moderate to Severe Plaque-type Psoriasis

United States, Czech Republic, Austria, Germany, India, Japan, Bulgaria, Singapore, Switzerland, United Kingdom, Italy, France, Poland, Slovakia, Canada, Vietnam
Novartis Pharmaceuticals

Completed

Extension Study of Secukinumab Prefilled Syringes in Subjects With Moderate to Severe Chronic Plaque-type Psoriasis Completing Preceding Psoriasis Phase III Studies With Secukinumab

Moderate to Severe Plaque-type Psoriasis

Germany, United States, Belgium, Colombia, Spain, Estonia, Hungary, Japan, Lithuania, Taiwan, Australia, Korea, Republic of, Canada, Singapore, Italy, Israel, Sweden, Guatemala, United Kingdom, Argentina, France, Poland, Latvia, Iceland, Finla... and more
Novartis Pharmaceuticals

Completed

4 Year Extension Study of Efficacy and Safety of Secukinumab in Patients With Moderate to Severe Chronic Plaque-type Psoriasis

Moderate to Severe Chronic Plaque-Type Psoriasis

United States, Germany, Japan, Bulgaria, Czechia, Singapore, Switzerland, United Kingdom, Italy, France, Vietnam, Poland, Slovakia, Austria, Canada
Galderma R&D

Completed

Efficacy & Safety of Nemolizumab in Subjects With Moderate-to-Severe Atopic Dermatitis

Moderate-to-Severe Atopic Dermatitis

United States, Belgium, Bulgaria, Estonia, France, Georgia, Germany, Hungary, Italy, Poland, Singapore
Galderma R&D

Active, not recruiting

Long-term Safety and Efficacy of Nemolizumab With Moderate-to-severe Atopic Dermatitis

Moderate-to-Severe Atopic Dermatitis

United States, Australia, Austria, Belgium, Bulgaria, Canada, Czechia, Estonia, France, Georgia, Germany, Hungary, Italy, Korea, Republic of, Latvia, Lithuania, Netherlands, New Zealand, Poland, Singapore, Spain, United Kingdom
TauRx Therapeutics Ltd

Completed

Safety and Efficacy Study Evaluating TRx0237 in Subjects With Behavioral Variant Frontotemporal Dementia (bvFTD)

Behavioral Variant Frontotemporal Dementia (bvFTD)

United States, Australia, Canada, Croatia, Poland, Netherlands, United Kingdom, Spain, Germany, Italy, Romania, Singapore
TauRx Therapeutics Ltd

Terminated

Open-Label Study of Leuco-methylthioninium Bis(Hydromethanesulfonate) (LMTM) in Subjects With Alzheimer's Disease or Behavioral Variant Frontotemporal Dementia (bvFTD)

Alzheimer's Disease | Behavioral Variant Frontotemporal Dementia

Korea, Republic of, United States, Spain, Taiwan, Canada, Belgium, Malaysia, United Kingdom, Australia, Singapore, Croatia, Finland, France, Germany, Netherlands, Romania, Russian Federation

Clinical Trials on Moderate Language Delay in Singapore

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in United Arab Emirates

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations